Addressing Immunogenicity Challenges to Select the Best Drug Development Candidate.

Published on April 4, 2022

De-risk and accelerate your programs by understanding some of the approaches to therapeutic protein immunogenicity risk assessment and how this helps you make better-informed candidate selection.

The post Addressing Immunogenicity Challenges to Select the Best Drug Development Candidate. appeared first on abzena.

Continue reading on website
Other news

Early Therapeutic Antibody Development: Addressing the Challenges to Expedite a CMC Program.

April 4, 2022
Learn how de-risk early-stage CMC and delivery of clinical trials material by addressing the challenges faced when therapeutic antibodies show less-than-ideal properties, from early development through to downstream manufacturing to pre-clinical and clinical studies.The post Early Therapeutic Antibody Development: Addressing the Challenges to Expedite a CMC Program. appeared first on abzena.

The Strategy Behind Your Journey to GMP with Emphasis on Linker Payload Development.

April 4, 2022
Develop lower risk strategies with our insights into the key considerations you need to factor in when conjugating your linker payload to its antibody in our review of the pros and cons of semi-synthetic and synthetic linker payloads.The post The Strategy Behind Your Journey to GMP with Emphasis on Linker Payload Development. appeared first on abzena.